Skip to main content

Focalin XR

(dexmethylphenidate XR)

Focalin XR (dexmethylphenidate hydrochloride); CII

Full Prescribing Information DailyMed Drug Information

Summary

Focalin XR is a once-daily, long-acting bead capsule of dexmethylphenidate, the more pharmacologically active d-threo enantiomer of racemic methylphenidate, approved for ADHD in children from age 6 and in adults. Half of each capsule is immediate-release beads and half enteric-coated delayed-release beads, producing two distinct plasma peaks rather than a flat curve. The capsule can be sprinkled on applesauce, making it the only dexmethylphenidate option for a patient who cannot swallow. Schedule II; brand and generic.

Forms & Strengths

  • Extended-release capsules: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg

Dosing

  • Age:
    • 6-17 y/o: safety and effectiveness established
    • 18 y/o and older: efficacy established at 20, 30 and 40 mg/day
    • Under 6 y/o: not recommended; higher plasma exposure and more adverse reactions, including weight loss, at the same dosage
  • Onset: ~ 30 min
  • Duration: up to 12 hours
  • Release Profile: 50% IR / 50% delayed-release via enteric-coated beads, giving two plasma peaks about 4 hours apart, the second at about 6.5 hours
  • Initial Dose:
    • New to methylphenidate, 6-17 y/o: 5 mg once daily in the morning
    • New to methylphenidate, 18 y/o and older: 10 mg once daily in the morning
    • Currently on racemic methylphenidate: half the current total daily dose
    • Currently on Focalin immediate-release tablets: the same total daily dose
  • Titration: 5 mg every 7 days (6-17 y/o); 10 mg every 7 days (18 y/o and older)
  • Max Dose: 30 mg/day (6-17 y/o); 40 mg/day (18 y/o and older)
  • Considerations: Once daily in the morning, with or without food. Swallow whole or open onto applesauce and take immediately without chewing. A capsule must never be divided.

Pharmacology

  • Mechanism: Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses
  • Delivery / Release: 50% IR / 50% delayed-release enteric-coated beads; two peaks roughly 4 hours apart. Against IR tablets at the same total dose, a lower second peak, higher trough, equivalent AUC.
  • Metabolism: De-esterified to d-ritalinic acid, little activity. Not a clinically relevant CYP substrate. Bioavailability 22% to 25%; half-life 2 to 3 hours; ~90% urinary.
  • Class Positioning: Duration comes from a second discrete release, not continuous delivery like the osmotic Concerta or the prodrug Azstarys, so some patients have a real interpeak dip in the early afternoon.

Indications

  • ADHD (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients 6 y/o and older, including adults

Off-Label Uses

  • Narcolepsy (ICD-10: G47.419): racemic methylphenidate carries the indication; this enantiomer does not. Insufficient.
  • ADHD in a child aged 4 to 5 (ICD-10: F90.x): behavioral parent training first (AAP 2019). This label goes further than lacking data: it states use below 6 is not recommended. Not the preschool methylphenidate.
  • Where the evidence does not support use. AHRQ 2024 grades stimulant head-to-head comparisons as low strength of evidence, so nothing supports choosing this over another long-acting methylphenidate, or any use outside ADHD in youth.

Contraindications & Warnings

  • Boxed Warning: Abuse, misuse, and addiction, which can lead to substance use disorder, overdose and death. Assess risk before prescribing and monitor throughout.
  • Contraindicated:
    • Hypersensitivity to methylphenidate or any component; angioedema and anaphylaxis reported.
    • Concomitant MAOI, or within 14 days of stopping one; hypertensive crisis.
  • Use with caution:
    • Structural cardiac abnormality, cardiomyopathy, serious arrhythmia or coronary disease; the label says avoid.
    • Pre-existing hypertension; expect a rise of 2 to 4 mmHg and 3 to 6 bpm.
    • Pre-existing psychosis or bipolar disorder; new psychotic or manic symptoms in ~0.1% of stimulant-treated patients.
    • Motor or verbal tics, and Tourette's syndrome.
    • Open-angle glaucoma, raised intraocular pressure, or significant hyperopia.
    • Peripheral vasculopathy including Raynaud's; substance use disorder in patient or household.
  • Screen before starting:
    • Cardiac disease by history, family history of sudden death, and exam. No routine ECG.
    • Personal and family history of tics or Tourette's syndrome.
    • Risk factors for mania; abuse and diversion risk; baseline height, weight, blood pressure and heart rate.

Drug Interactions

  • MAOIs (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Do not co-prescribe; allow 14 days after stopping.
  • Antihypertensives (any class): effectiveness may fall. Monitor blood pressure and adjust their dose.
  • Halogenated anesthetics (sevoflurane, isoflurane, desflurane): sudden intraoperative pressure and rate rise. Avoid on the day of surgery.
  • Risperidone: a dose change either way may raise EPS risk. Monitor for EPS across any change.
  • Serotonergic agents (SSRIs, SNRIs, TCAs, triptans): serotonin syndrome appears postmarketing, not in the interaction table. Counsel and reassess when adding one.

Administration

  • Once daily in the morning, with or without food.
  • Swallow whole, or sprinkle the entire contents onto applesauce and eat it all immediately without chewing. Do not store a mixed dose.
  • Never divide a capsule. Adjust by strength, not by splitting.
  • Switching from racemic methylphenidate: half the total daily dose. From Focalin tablets: the same total daily dose. The two rules differ; this is the commonest conversion error here.
  • Stop the drug if a month of dose adjustment brings no improvement. Store securely, preferably locked.

Side Effects

  • Common (pediatric controlled trial): decreased appetite 30% vs 9%, headache 25% vs 11%, dyspepsia 8% vs 4%, anxiety 6% vs 0%. Dose related: insomnia rose from 5% at 10 mg/day to 17% at 30 mg/day, vomiting from 2% to 9%.
  • Serious:
    • Sudden death with structural cardiac disease; avoid use, and evaluate exertional syncope promptly.
    • New psychosis or mania, including with no psychiatric history; consider discontinuing.
    • Priapism, sometimes requiring surgery, including during drug holidays. Immediate care.
    • Peripheral vasculopathy including Raynaud's, with digital ulceration; reduce dose or stop.
    • Growth suppression: mean weight change minus 0.5 kg on drug against plus 0.4 kg on placebo over 7 weeks. Interrupt if a child is not gaining.
    • Acute angle closure glaucoma and raised intraocular pressure.
    • Angioedema and anaphylaxis.

Monitoring & Labs

  • Cardiovascular: blood pressure and heart rate at baseline, at every dose change, and at least every 6 months. A rise beyond the expected 2 to 4 mmHg triggers dose reduction.
  • Growth: height, weight and BMI at baseline and every 6 months, more often in the first year; this label documents net weight loss over 7 weeks.
  • Appetite and sleep: at every visit and dose change. Insomnia triples between 10 mg and 30 mg here, so treat it as a dose signal first.
  • Afternoon coverage: ask about the early to mid afternoon at each visit; a dip there is a formulation problem, not necessarily a dose problem.
  • Psychiatric and tics: screen for new psychosis, mania, aggression and emergent tics at every visit. Inspect fingers and toes for colour change or ulceration.
  • Abuse and diversion: at every refill reassess risk, reconcile the pill count, and check the state PDMP per state requirement.
  • Laboratory: no routine laboratory monitoring is required.

Discontinuation & Taper

  • May be stopped abruptly at therapeutic doses; this label gives no taper instruction.
  • After prolonged use expect withdrawal: dysphoria, fatigue, vivid dreams, sleep change, increased appetite, agitation.
  • Priapism has occurred during withdrawal and planned holidays; mention it before a holiday in an adolescent male.
  • A drug holiday is a skipped morning dose. There is no partial-dose option, since capsules must not be divided.

Pregnancy & Lactation

  • Pregnancy: Published studies and postmarketing reports have not identified a drug-associated risk. Stimulants reduce placental perfusion. Delayed fetal ossification in rats at 5 times the maximum human dose; spina bifida in rabbits at 200 mg/kg/day.
  • Lactation: Present in milk; infant doses were 0.16% to 0.7% of the maternal weight-adjusted dose, with no reported infant effects. Monitor for agitation, insomnia, poor feeding and low weight gain.
  • Dexmethylphenidate specifically: no clinical use data in lactation; a maternal requirement is not a reason to stop breastfeeding. (LactMed 2025)
  • Exposure Registry: National Pregnancy Registry for ADHD Medications, 1-866-961-2388, https://womensmentalhealth.org/adhd-medications/

Counseling Points

  • Counsel the family on:

    • The two-peak shape of the day: some children dip in the early afternoon. Ask them to note when in the day the trouble happens.
    • Coverage running about 12 hours, so a child dosed at 7 a.m. does homework and dinner off medication.
    • The sprinkle method: onto applesauce, eaten at once, never chewed, never saved. Chewing destroys the delayed-release half.
    • That the milligram number is deliberately half what a racemic methylphenidate bottle showed, and is not a dose reduction.
    • Appetite suppression: move the largest meal to breakfast and to the evening.
    • Locked storage, and that sharing a Schedule II medication is a felony.

  • Advise them to call for:

    • Chest pain, fainting, or a racing heart that does not settle.
    • New hallucinations, or new suspicious, fearful or grandiose thinking.
    • Numbness or colour change in the fingers or toes; eye pain or blurred vision.
    • A new tic, or a marked worsening of an existing one.
    • Weight loss, or clothes fitting more loosely over a few weeks.
    • Insomnia appearing or worsening after a dose increase.
    • A painful erection lasting more than a few hours, including during a planned break.

References

  1. DailyMed. Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules prescribing information. Novartis. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a1da905-42a0-4748-9c39-67eca45deccc
  2. LactMed. Dexmethylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK500764/
  3. FDA. National Drug Code Directory, openFDA. Queried by generic name dexmethylphenidate. 2026. https://api.fda.gov/drug/ndc.json
  4. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/
  5. AHRQ. ADHD diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK603001/
Back to top